Overview

• Hims & Hers reported Q2 revenue of $544.8 million, a 73% increase year-over-year but below the $552 million analysts predicted.
• Adjusted EPS of $0.17 and adjusted EBITDA of $82 million both surpassed consensus estimates, marking significant profitability gains.
• The company projected Q3 revenue of $570 million to $590 million, under the $583 million StreetAccount forecast, and EBITDA of $60 million to $70 million.
• Shares declined about 9% in extended trading as disappointing guidance outweighed beats on earnings and cash flow.
• Hims & Hers continues to sell compounded GLP-1 therapies and faces heightened FDA scrutiny after its collaboration with Novo Nordisk collapsed over compliance issues.